1949
DOI: 10.1016/s0140-6736(49)90423-7
|View full text |Cite
|
Sign up to set email alerts
|

Dextran as a Plasma Substitute

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
17
0

Year Published

1950
1950
2013
2013

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 78 publications
(18 citation statements)
references
References 4 publications
1
17
0
Order By: Relevance
“…per minute. That venous pressure is elevated following dextran injection, has been shown by several investigations (2,3,18).…”
Section: Methodsmentioning
confidence: 69%
See 1 more Smart Citation
“…per minute. That venous pressure is elevated following dextran injection, has been shown by several investigations (2,3,18).…”
Section: Methodsmentioning
confidence: 69%
“…It has been well established that partially hydrolyzed dextran is effective in expanding and maintaining the plasma volume (1)(2)(3). Previously, there have been numerous investigations concerning the effects of plasma volume expansion on the circulatory dynamics (4-7).…”
Section: Introductionmentioning
confidence: 99%
“…In these experiments this sum was 45, 41, 39, and 46 grams at 1, 6, 12 and 24 hours, respectively. Bull and associates (13) have indicated this in another manner by stating that "the main function of the substitute would clearly be to restore circulating blood volume until the patient's own plasma protein returned to the circulation." Since dextran fulfills this criterion, it must be considered as a satisfactory plasma volume expander.…”
Section: Methodsmentioning
confidence: 99%
“…BP was 120/75. There was 4 + albuminuria, 6 RBC/hpf, specific gravity 1.037. A normochromic anemia and leucocytosis were present.…”
Section: Sum Marymentioning
confidence: 98%
“…Thus the efficacy of repeated plasma or serum albumin infusions carries with it dangers of reactions as well as certain economic burdens (1)(2)(3). Plasma substitutes such as gelatin, polymerized glucose ("Dextran"), or polyvinyl pyrrolidone ("Periston"), have not received sufficiently prolonged clinical trials to exclude the possibility of sequellae such as those which follow acacia therapy (4)(5)(6)(7). Similarly, certain practical obstacles attend the application of instruments available for vivodialysis, even when they function efficiently in reducing extracellular volume.…”
mentioning
confidence: 99%